Table 1 Overview of SGLT2 inhibitor CVOTs

EMPA-REG OUTCOME

(empagliflozin)

[16, 33]

NCT01131676

Completed 2015; results published

Time to first occurrence of 3P-MACE

4P-MACE; CV death; death by any cause; symptomatic MI; symptomatic non-fatal MI; silent MI; hospitalisation for unstable angina; coronary revascularisation procedure; stroke; non-fatal stroke; TIA; HHF; HHF or CV death excluding stroke; incident or worsening nephropathy or CV death; incident or worsening nephropathy; progression to macroalbuminuria; dSCr and eGFR ≤45 ml/min/1.73m²; initiation of RRT; dSCr and eGFR ≤45 ml/min/1.73m², initiation of RRT or renal death; incident albuminuria in patients with normal albumin at baseline

CANVAS Program (canagliflozin)

[17, 34]

NCT01032629 (CANVAS) & NCT01989754 (CANVAS-R)

Completed 2017; results published

Time to first occurrence of 3P-MACE

Death by any cause; CV death; progression of albuminuria; CV death or HHF; non-fatal MI; non-fatal stroke; MI; stroke; hospitalisation for any cause; HHF; new-onset albuminuria; new-onset microalbuminuria; new-onset macroalbuminuria; dSCr, ESRD or renal death; dSCr, ESRD, renal death or new-onset macroalbuminuria; dSCr, ESRD, renal death or CV death; ≥40% decrease in eGFR, ESRD or renal death; ≥40% decrease in eGFR, ESRD, renal death or new-onset macroalbuminuria; ≥40% decrease in eGFR, ESRD, renal death or CV death; 40% reduction in eGFR; dSCr; ESRD; ESRD or renal death

DECLARE-TIMI 58 (dapagliflozin)

[18]

NCT01730534

Completed 2018; results published

Time to first occurrence of 3P-MACE

Time to first occurrence of CV death or HHF

≥40% decrease in eGFR to eGFR < 60 ml/min/1.73m², ESRD, renal death or CV death; death by any cause; ≥40% decrease in eGFR to eGFR < 60 ml/min/1.73m², ESRD or renal death; HHF; MI; ischaemic stroke; CV death; non-CV death

VERTIS-CV (ertugliflozin)

[35]

NCT01986881

Estimated completion 2019

Time to first occurrence of 3P-MACE

Results not yet reported